Product news

Share this article:

Boehringer Ingelheim Pharmaceuticals announced that the FDA has granted full approval of Aptivus (tipranavir) capsules. The full approval of Aptivus based largely on 48-week analyses of the Phase III pivotal clinical studies known as the RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) trials. These trials comprise one of the largest study programs conducted in treatment-experienced HIV patients. The FDA granted accelerated approval to Aptivus in June 2005. Accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.